Patents by Inventor Silvia Comis

Silvia Comis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of kinase inhibitor for the treatment of thymoma
    Patent number: 8580793
    Abstract: The invention provides a low molecular weight ATP-competitive CDK inhibitor and TRKA inhibitor of formula (I) for use in the treatment of thymoma and thymic carcinoma. The compound can be administered together with one or more cytotoxic or cytostatic agents.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: November 12, 2013
    Assignee: Nerviano Medical Services S.r.l.
    Inventors: Angela Scaburri, Maria Adele Pacciarini, Marina Ciomei, Bernard Laffranchi, Silvia Comis
  • USE OF KINASE INHIBITOR FOR THE TREATMENT OF THYMOMA
    Publication number: 20120077819
    Abstract: The invention provides a low molecular weight ATP-competitive CDK inhibitor and TRKA inhibitor of formula (I) for use in the treatment of thymoma and thymic carcinoma. The compound can be administered together with one or more cytotoxic or cytostatic agents.
    Type: Application
    Filed: March 15, 2010
    Publication date: March 29, 2012
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Angela Scaburri, Maria Adele Pacciarini, Marina Ciomei, Bernard Laffranchi, Silvia Comis
  • METHOD OF ADMINISTERING AN ANTITUMOR COMPOUND
    Publication number: 20100256160
    Abstract: The present invention provides a method of treating a mammal, including humans, suffering from tumour, comprising administering Compound 1 of the formula A or a pharmaceutically acceptable salt thereof, to said mammal by intravenous infusion, characterised in that Compound 1 is conveniently administered employing particular schedules, infusion times and doses which allow a more efficacious treatment. Compound 1 of formula A is an aurora inhibitor, chemical name N-{5-[(2R)-2-methoxy-2-phenylethanoyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-4-(4-methylpiperazin-1-yl)benzamide, and the method is preferably for the treatment of patients having solid tumours or hematopoietic malignant tumours.
    Type: Application
    Filed: October 25, 2007
    Publication date: October 7, 2010
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Bernard Laffranchi, Jurgen Moll, Fabrina Bologna, Silvia Comis